Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases

Abstract

Introduction

The advent of immune checkpoint inhibitors in the treatment of certain types of cancers has revolutionized cancer therapy. In general, these novel agents are more tolerable and have better safety profiles than conventional chemotherapy agents. Although a low incidence of myocarditis was noted as a side effect of immune checkpoint inhibitors in clinical trials, it is being increasingly cited in the literature as their use also increases.

Methods

Using a combination of search terms in the PubMed/Medline database and manual searches on Google Scholar and the bibliographies of articles identified, we reviewed all cases reported in the English language citing myocarditis associated with either pembrolizumab, nivolumab, ipilimumab, or any combination of these agents.

Results

A total of 42 cases were included in the study. Mean age was 65.5 years; 64% were male, 36% were female. One or two doses preceded the onset of myocarditis in 33% and 29% of cases, respectively. Steroids were used as the first-line therapy in 90% of cases. Complete heart block occurred in 36% of cases. Fourteen (33%) deaths were reported, with 64% and 29% of deaths occurring after one or two doses, respectively.

Conclusion

Most cases and fatalities of myocarditis occurred shortly after initiation of immune checkpoint inhibitor therapy. Arrhythmias, particularly complete heart block, appear to be related to the occurrence of more severe and fatal cases. The use of serial electrocardiograms or biomarkers of myocardial injury may be crucial in detecting early stages of the disease process. Further research establishing more specific guidelines is necessary in dealing with this potentially fatal side effect.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbe C (2017) Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167:683–684. https://doi.org/10.7326/L17-0396

  2. Baldetti L, Melillo F, Beneduce A, Camici PG (2018) Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jey191

  3. Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27:155–158. https://doi.org/10.1097/cmr.0000000000000314

  4. Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr (2017) Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 19:682–685. https://doi.org/10.1002/ejhf.806

  5. Blauwet LA, Cooper LT (2010) Myocarditis. Prog Cardiovasc Dis 52:274–288. https://doi.org/10.1016/j.pcad.2009.11.006

  6. Bracamonte-Baran W, Cihakova D (2017) Cardiac autoimmunity: myocarditis. Adv Exp Med Biol 1003:187–221. https://doi.org/10.1007/978-3-319-57613-8_10

  7. Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14:247–249. https://doi.org/10.1200/JOP.18.00005

  8. Caforio AL et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326–1333. https://doi.org/10.1093/eurheartj/ehm076

  9. Caforio ALP, Malipiero G, Marcolongo R, Iliceto S (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63. https://doi.org/10.1007/s11886-017-0870-x

  10. Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB (2018) Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 56:667–671. https://doi.org/10.1080/15563650.2017.1401079

  11. Collin M (2016) Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat 26:555–564. https://doi.org/10.1080/13543776.2016.1176150

  12. Cooper LT et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914–1931. https://doi.org/10.1016/j.jacc.2007.09.008

  13. Copeland-Halperin R, Sahni GD (2018) Autoimmune Myocarditis With AV Block: Too Much of a Good Thing? JACC

  14. Cristina AADLA, Escudier-Villa JM, Ortega Marcos J, Silva-Melchor L (2017) Progressive exertional dyspnea and fatigue in an oncology-patient. Austin J Clin Cardiolog 4(2):1058

  15. Curtis JR et al (2007) Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46:1688–1693. https://doi.org/10.1093/rheumatology/kem212

  16. Escudier M et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571

  17. Farhad H et al (2016) Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 9:15. https://doi.org/10.1161/circimaging.115.003584

  18. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36:227–232

  19. Frigeri M et al (2018) Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34:92 e91–92 e93. https://doi.org/10.1016/j.cjca.2017.09.025

  20. Fukasawa Y et al (2017) Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 10:809–812. https://doi.org/10.1159/000479958

  21. Fung G, Luo H, Qiu Y, Yang D, McManus B (2016) Myocarditis. Circ Res 118:496–514. https://doi.org/10.1161/CIRCRESAHA.115.306573

  22. Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA (2019) Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. https://doi.org/10.1093/ehjcr/yty149

  23. Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879–886. https://doi.org/10.1634/theoncologist.2018-0130

  24. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3:4. https://doi.org/10.1186/s40425-015-0048-2

  25. Gibson R, Delaune J, Szady A, Markham M (2016) Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-216228

  26. Guglin M, Nallamshetty L (2012) Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 14:637–651. https://doi.org/10.1007/s11936-012-0204-7

  27. Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001

  28. Hauck AJ, Kearney DL, Edwards WD (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64:1235–1245

  29. Heinzerling L et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. https://doi.org/10.1186/s40425-016-0152-y

  30. Imai R, Ono M, Nishimura N, Suzuki K, Komiyama N, Tamura T (2018) Fulminant myocarditis caused by an immune checkpoint inhibitor: a case report with pathological findings. J Thorac Oncol 15:15. https://doi.org/10.1016/j.jtho.2018.10.156

  31. Inayat F, Masab M, Gupta S, Ullah W (2018) New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-223252

  32. Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A (2018) Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 41:332–335. https://doi.org/10.1097/CJI.0000000000000239

  33. Janardhanan R (2016) Myocarditis with very high troponins: risk stratification by cardiac magnetic resonance. J Thorac Dis 8:E1333–E1336. https://doi.org/10.21037/jtd.2016.10.60

  34. Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755. https://doi.org/10.1056/NEJMoa1609214

  35. Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57:3157–3162. https://doi.org/10.2169/internalmedicine.0255-17

  36. Kindermann I et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792. https://doi.org/10.1016/j.jacc.2011.09.074

  37. Kobashigawa JA et al (2006) Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transpl 6:1377–1386. https://doi.org/10.1111/j.1600-6143.2006.01290.x

  38. Kobashigawa J et al (2011) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transpl 30:252–269. https://doi.org/10.1016/j.healun.2010.11.003

  39. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11. https://doi.org/10.1186/s40425-015-0057-1

  40. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30:1354–1359

  41. Lopez EM, Dunn S, Mazimba S (2018) Malignant arrhythmias in autoimmune myocarditis secondary to immune checkpoint blockade treatment. J Am College Cardiol 71:A2375. https://doi.org/10.1016/S0735-1097(18)32916-4

  42. Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A (2007) CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 101:248–257. https://doi.org/10.1161/circresaha.106.147124

  43. Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037

  44. Mahrholdt H et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258. https://doi.org/10.1161/01.CIR.0000118493.13323.81

  45. Martinez-Calle N et al (2018) Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica 103:318–321. https://doi.org/10.3324/haematol.2017.185777

  46. Matson DR, Accola MA, Rehrauer WM, Corliss RF (2018) Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci 63:954–957. https://doi.org/10.1111/1556-4029.13633

  47. Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S (2016) Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 26:319–320. https://doi.org/10.1097/CMR.0000000000000251

  48. Monge C et al (2018) Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer 6:150. https://doi.org/10.1186/s40425-018-0473-0

  49. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933. https://doi.org/10.1016/S0140-6736(18)30533-6

  50. Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J, Robert C (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91:171–173. https://doi.org/10.1016/j.ejca.2017.11.026

  51. Nieminen MS, Heikkila J, Karjalainen J (1984) Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol 53:1331–1337

  52. Norwood TG et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5:91. https://doi.org/10.1186/s40425-017-0296-4

  53. Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483. https://doi.org/10.1038/nm955

  54. Reuben A et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097. https://doi.org/10.1080/2162402X.2017.1361097

  55. Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM 3rd (2005) Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transpl 5:2778–2785. https://doi.org/10.1111/j.1600-6143.2005.01074.x

  56. Rota E et al (2019) Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurological Sci 14:4–5. https://doi.org/10.1016/j.ensci.2018.11.023

  57. Sakai T, Sasada S, Jyo C, Ishioka K, Takahashi S, Nakamura M (2017) Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer. Ann Oncol 28:mdx697.072–mdx697.072. https://doi.org/10.1093/annonc/mdx697.072

  58. Samara Y, Yu CL, Dasanu CA (2018) Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract 15:1078155218755868. https://doi.org/10.1177/1078155218755868

  59. Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 99:117–119. https://doi.org/10.1016/j.lungcan.2016.06.025

  60. Simsek M, Tekin SB, Bilici M (2019) Immunological agents used in cancer treatment. Eurasian J Med 51:90–94. https://doi.org/10.5152/eurasianjmed.2018.18194

  61. Tadokoro T, Keshino E, Mohri M (2016) A case of acute myocarditis during treatment with anti-PD-1 antibody nivolumab in a melanoma patient. J Cardiac Fail 22:220. https://doi.org/10.1016/j.cardfail.2016.07.355

  62. Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L (2018) Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 41:35–38. https://doi.org/10.1097/CJI.0000000000000190

  63. Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876–4884. https://doi.org/10.4049/jimmunol.1200389

  64. Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A (2017) Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921–924. https://doi.org/10.1038/bjc.2017.253

  65. Thibault C, Vano Y, Soulat G, Mirabel M (2018) Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J 39:3553. https://doi.org/10.1093/eurheartj/ehy485

  66. Varricchi G et al (2017) Cardiotoxicity of immune checkpoint inhibitors ESMO Open 2:e000247. https://doi.org/10.1136/esmoopen-2017-000247

  67. Weber JS (2012) Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ 15:174–177. https://doi.org/10.14694/edbook_am.2012.32.174

  68. Yamaguchi S et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812.e811–812.e813. https://doi.org/10.1016/j.cjca.2018.03.007

Download references

Funding

None.

Author information

Correspondence to Suheil Albert Atallah-Yunes.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Atallah-Yunes, S.A., Kadado, A.J., Kaufman, G.P. et al. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145, 1527–1557 (2019). https://doi.org/10.1007/s00432-019-02927-x

Download citation

Keywords

  • Myocarditis
  • Immune checkpoint inhibitors
  • Immunotherapy